Buckley mayor fined nearly $15k over missing campaign forms
Buckley Mayor Beau Burkett has racked up a bill of nearly $15,000 worth in fines.
The fines are mostly related to breaking campaign finance laws, including having late or missing financial disclosures, according to The Tacoma News Tribune. The latest fine was a $1,000 charge filed last week for not reporting personal debt on a 2023 form, with his total amount owed reaching $14,850 in fines.
The Public Disclosure Commission (PDC) states that all elected officials must file financial statements to ensure transparency. Candidates running for public office in Washington must file an F-1 Personal Financial Affairs Statement, which documents the candidate's salary range, the real estate they own, and membership on boards of committees, among other important information.
According to The Tacoma News Tribune, Burkett did not turn in F-1 forms for 2015, 2016, 2017, 2018, and 2019. In 2021, while running in the mayoral race, he didn't turn in his 2020 F-1 or his C-1 candidate registration form. When requested to file the paperwork accordingly, he failed to include and disclose the $13,850 he owed in fines to the PDC.
'Mayor Burkett is one of the approximately 5-10% of people who don't correct their forms when contacted by PDC staff,' Edwards wrote in an email to The News Tribune. 'Despite this, and despite the many thousands of dollars that Mayor Burkett already owes the agency for years of ignoring the law, the PDC still offered to suspend virtually all of today's penalty if he corrects his F1 report.'
Burkett did not appear at last week's hearing. KIRO Newsradio has reached out for comment. Burkett's term as mayor ends December 31, and the fines have been sent to collections.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
17 minutes ago
- CNBC
Meta shares fall on AI restructuring report, while Lilly shrugs off Novo's Ozempic price move
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks aren't moving much Monday as Wall Street waits on retail earnings and a speech from Fed Chair Jay Powell later in the week. Monday's session lacks clear themes, but Meta Platforms stands out as a laggard after a report from The Information said the longtime Club holding is planning the fourth restructuring of its AI team in six months. The story is raising questions in light of Meta's significant investment in recruiting AI talent from other tech companies. Novo price cut : Shares of Club name Eli Lilly are relatively unchanged despite chief rival Novo Nordisk lowering prices for its popular GLP-1 medication. Novo Nordisk announced on Monday that it has cut the price of Ozempic, its popular GLP-1 for Type 2 diabetes, to $499 per month for cash-paying patients that use its NovoCare direct-to-patient program. Novo also announced that it has partnered with GoodRx to offer the same price for Ozempic and the weight-loss drug Wegovy at U.S. pharmacies. While the news may spark concerns that a price war is heating up in a battle for market share, we don't see this specific Ozempic development advancing that narrative. The main reason why is that the cash-pay market for GLP-1s to treat Type 2 diabetes is not as important as it is for their obesity counterparts. It all comes down to insurance coverage, which is much higher for these medications for diabetes than weight loss. Indeed, Lilly does not offer Type 2 diabetes treatment Mounjaro on its LillyDirect platform, while sister drug Zepbound for obesity is on there. Lilly executives were asked about this on the company's August earnings call, and the president of Lilly USA, Ilya Yuffa, had this to say: "With Mounjaro, we have significant coverage. So, over 90% coverage in both commercial as well as [Medicare] Part D. And so, we're not sure if [adding Mounjaro to LillyDirect] necessarily provides additional avenue. With Zepbound, we see significant growth because we do have coverage gaps in commercial. And obviously, we also have coverage gaps without having the ability to cover anti-obesity medications in Part D. So, we see this as an opportunity for us to meet that need. For what it's worth, we still like where Lilly sits in the obesity side of the GLP-1 market. Back in February, Eli Lilly announced that self-pay patients could get Zepbound single dose vials for $499 per month through its LillyDirect platform. That's on par with the price for Wegovy on NovoCare. Since head-to-head studies have found Lilly's Zepbound to be superior to Novo Nordisk's Wegovy on weight loss, patients should continue to prefer Lilly's GLP-1s. We initially downgraded our rating on Eli Lilly after its earnings a few weeks ago, partly due to concerns about a potential price war. However, we reversed course and upgraded the stock back to a buy-equivalent 1 following signs of confidence driven by significant insider buying activity. Nuclear win : Alphabet's Google and the nuclear energy company Kairos Power announced on Monday the deployment of an advanced nuclear plant to the grid. Per the agreement, a reactor operated by Kairos Power will deliver up to 50 megawatts of reliable, 24/7 energy to the Tennessee Valley Authority electric grid that powers Google data centers in Tennessee and Alabama. The electricity will come from Kairos' Hermes 2 plant, which is scheduled to begin operations in 2030. The collaboration underscores how hyperscalers are creating new partnerships with nuclear energy providers to secure, around-the-clock power supply toward the end of the decade. Unlike gas-fired electricity, nuclear power offers tech giants like Alphabet a way to run their data centers on clean energy while advancing their decarbonization goals. While Club name GE Vernova is probably best known for its heavy-duty gas turbines , the power generation company also makes small modular reactors that have gained in popularity, so nuclear developments are important to follow closely. Up next: Palo Alto Networks reports after the closing bell , the first of three Club stocks with earnings this week. Before the opening bell on Tuesday, we'll see earnings from Club name Home Depot , Medtronic , and Viking Holdings . On the data side, we'll see July housing starts and building permits, but we'll take are cue on the housing sector from what Home Depot management says on the earnings call. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Business of Fashion
an hour ago
- Business of Fashion
GLP-1 Pills Will Be Priced Similarly to Injections, Wall Street Predicts
US prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. US list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. ADVERTISEMENT The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4 percent after 72 weeks in a trial. That compares with weight loss of 15 percent for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21 percent. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is 'probably going to come on par with the current drugs today or slightly lower,' Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. Growing Cash Pay US doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40 percent of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce US prices. Novo declined to comment on pricing, pointing to Aug. 6 comments by David Moore, its US operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. ADVERTISEMENT Manufacturing Volume A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the US market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. 'It's all about scale and pricing,' said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. The pill form requires about 75 times more active ingredient than the highest-dose Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. 'Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy,' Andersen added. By Maggie Fick and Bhanvi Satija; Editors: Caroline Humer and Will Dunham Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis.
Business Insider
2 hours ago
- Business Insider
Quantum Computing News: Rigetti Scales, Nvidia Adds Tools, Amazon Speeds Cloud Runs
Welcome to another weekly recap, where we look at key updates in quantum computing, as the industry continues to move forward at a pace. Today, we follow fresh steps in scale and error control. First, Rigetti Computing (RGTI) has advanced its chiplet design, then Terra Quantum shows a new way to cut errors, and next, Nvidia (NVDA) adds tools for faster codes. We also note new cloud features from Amazon (AMZN) and fresh results from Quantum Computing Inc. (QUBT). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Rigetti Computing: Scaling with Chiplets We start this week with Rigetti Computing (RGTI), which has reported progress in its chiplet-based design. The company introduced Cepheus-1-36Q, a 36-qubit system built on a modular layout. The design doubles the performance of its earlier Ankaa-3 platform, cutting error rates by half and reaching a median gate fidelity of 99%. Rigetti says it plans to scale further, with a 100-plus qubit system targeted before the end of 2025. The company also strengthened its finances with a $350 million equity raise, bringing cash to $571.6 million and leaving it with no debt. Rigetti aims to use the funds for internal work, new deals, and future growth. Terra Quantum: New Error Correction Method Next, we move to Terra Quantum, which announced a method called QMM-Enhanced Error Correction. The new layer improves error handling on today's hardware without changes to the design. Tests on IBM (IBM) processors showed up to 35% lower error, with logical fidelity raised to 94%. The method works with fewer qubits than standard codes, making it more efficient for early systems. Terra Quantum says the design can also boost quantum machine learning by cutting training loss and improving run stability. Quantum Computing Inc: Wider Loss, Stronger Balance Quantum Computing Inc (QUBT) posted a wider quarterly loss of $36.5 million, with revenue falling to $61,000. The drop came from higher operating costs and a non-cash warrant charge. However, the company's cash position rose to $348.8 million after a private placement. Additionally, QCi opened a photonic chip foundry in Arizona, reported new sales in sensing and AI, and gained index inclusion in the Russell 3000 and 2000 (IWM). The company also secured deals with NASA and shipped devices for research use in Europe and Asia. Nvidia: CUDA-QX Update Moving on to the mega-cap companies, first is Nvidia, which has released CUDA-QX 0.4, adding tools for error correction and new solvers. The update includes a generative AI model that designs circuits adaptively, plus a GPU-powered tensor network decoder for faster and more accurate work. The company says the framework now allows researchers to design, simulate, and test codes all in one environment, backed by its cuQuantum libraries. The release is open-source and tuned to work across both simulation and hardware. Amazon: Faster Braket Runs We finish with Amazon expanding its Braket service with 'program sets.' The feature lets users bundle up to 100 circuits into one task, cutting run times by up to 24 times. It also reduces costs since the per-task fee is paid once per batch instead of per circuit. Program sets are now live on Rigetti and IQM devices, as well as on Braket's simulator, with more platforms expected to follow. We used the TipRanks' Comparison Tool to line up some of the top quantum stocks with a few names mentioned in this piece. It's an easy way to see how they compare and get a feel for where the space might be going.
